• CO263 Utility Values From Pooled Analysis of High Concentration (179 mg) Capsaicin Patch (HCCP) Studies In Peripheral Neuropathic Pain (PNP)

    Dec 1, 2025, 00:00

  • PCR67 Effectiveness of Vonoprazan on Health-Related Quality of Life and Sleep Quality in Chinese Patients With Reflux Esophagitis: Post Hoc Analysis of the VIEW Study

    Dec 1, 2025, 00:00

  • EPH156 Large Language Model (LLM) as Catalyst for Rapid and Efficient Critical Appraisal of Epidemiological Research

    Dec 1, 2025, 00:00

  • PT5 Pulmonary Nodule (PN)-Related and Lung Cancer-Related Workup Costs Within the Two-Year Period After Diagnosis of a PN in the United States

    Dec 1, 2025, 00:00

  • EE303 Cost-Utility Analysis of Iptacopan vs. C5 Inhibitors in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Naïve to Complement Inhibitors in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • EPH194 Productivity Costs Due to Respiratory Infections in Denmark: A Potential for Prophylaxis

    Dec 1, 2025, 00:00

  • EE293 Cost-Savings Assessment of Fitusiran Prophylaxis in Minimizing Breakthrough Bleeding Treatment Expenses in the United Arab Emirates

    Dec 1, 2025, 00:00

  • CO81 Economic and Clinical Burden of Diagnosed Congenital Cytomegalovirus Disease in France During the First 2 Years of Life

    Dec 1, 2025, 00:00

  • PT42 Comparative Effectiveness of Second-Line Antidiabetic Medications on the Risk of Major Adverse Cardiovascular Events: A Real-World Study in China

    Dec 1, 2025, 00:00

  • CO56 Comparative Efficacy of Asciminib vs. Second-Generation TKIs in Newly Diagnosed PhCML Using Unanchored Matching-Adjusted Indirect Comparisons

    Dec 1, 2025, 00:00

  • EPH208 Respiratory Syncytial Virus (RSV) Knowledge and Perceived RSV Risk Groups Amongst GP/PCPs and Specialists in APAC: A Cross-Sectional Knowledge Attitude and Practices Survey (RESVIKAP)

    Dec 1, 2025, 00:00

  • RWD13 AI for Precision Oncology Eviden Case Study Research From British Columbia, Canada

    Dec 1, 2025, 00:00

  • HTA325 The Perils of Treatment Crossover in Clinical Trials

    Dec 1, 2025, 00:00

  • HPR57 Distributional Cost-Effectiveness Analysis Across the Globe: How Feasible Is It Really?

    Dec 1, 2025, 00:00

  • EE358 Economic Burden of COPD in Algeria: A Retrospective Analysis of Healthcare Resource Utilization and Costs

    Dec 1, 2025, 00:00

  • EE515 Healthcare Resource Utilization and Economic Burden Among Caregivers of Individuals With Autism Spectrum Disorder Caregiver: Findings From the 2024 5EU National Health and Wellness Survey

    Dec 1, 2025, 00:00

  • HTA332 The Soft Science in Hard Decisions: Utility of Qualitative Evidence in HTA Decisions

    Dec 1, 2025, 00:00

  • HPR104 From Policy to Practi Are Larger Member States Leading the Way for Joint Clinical Assessments?

    Dec 1, 2025, 00:00

  • SA100 Use of Innovative Methods in Long-Term Follow-up Observational Studies: An AI-Enabled Targeted Literature Review

    Dec 1, 2025, 00:00

  • MSR169 Predicting Outcomes and Estimating Minimum Sample Sizes for Divozilimab Efficacy in NMOSD: A Clinical Trial Simulation and Unanchored Matching-Adjusted Indirect Comparison

    Dec 1, 2025, 00:00

  • MSR103 Exploring Meaningful Change in Digital Health Technologies via Qualitative Interviews

    Dec 1, 2025, 00:00

  • PCR65 Diagnostic Odyssey of Patients With the Rare Immunodeficiency-Activated PI3 Kinase Delta Syndrome (APDS): Case Study With Expert Interviews and Patient Surveys

    Dec 1, 2025, 00:00

  • MT1 A Comparative Analysis of the Nordic Market Access Pathways for Medical Devices

    Dec 1, 2025, 00:00

  • EE25 A Novel View on the Treatment Costs of Relapsed or Refractory Diffuse Large B-cell Lymphoma From the Brazilian Private Healthcare System Perspective: A First- to Third-Line Analysis

    Dec 1, 2025, 00:00

  • EE286 Costs and Healthcare Resource Utilization Associated With Generalized Myasthenia Gravis: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE250 Cost-Effectiveness of Familial Hypercholesterolemia Cascade Testing in Thailand: A Comparative Analysis of Exome vs. Long-Read DNA Sequencing

    Dec 1, 2025, 00:00

  • EPH47 Colorectal Cancer Mortality Overview in Mexico 1998-2023

    Dec 1, 2025, 00:00

  • PCR182 Patient-Reported Outcomes After Total Knee Arthroplasty: Comparisons Across TKA Procedures and PRO Domains

    Dec 1, 2025, 00:00

  • HPR66 Early Impact of the Mazars Review on Reimbursement Timelines in Ireland

    Dec 1, 2025, 00:00

  • MSR146 Metamodels SHAP Analysis: Unearthing Data Interactions

    Dec 1, 2025, 00:00

  • RWD30 Characteristics of Real-World Data Landscape in Spain: A Scoping Review

    Dec 1, 2025, 00:00

  • HTA260 Optimizing PICO Scoping in EU HTA: Lessons From a HTA Coordination Group PICO Exercise in Advanced NSCLC to Inform Future Best Practice

    Dec 1, 2025, 00:00

  • RWD100 Improving Access to German Health Claims Data Through Synthetic Data Generation: Findings and Achievements of a Holistic Evaluation

    Dec 1, 2025, 00:00

  • ISPOR Europe 2025: Powering Value and Access Through Patient-Centered Collaboration

    Dec 1, 2025, 00:00

  • PCR266 We Hear What You Are Saying: The Development and Design of the Qualitative Interview Feedback Survey (QIFS) for Use in Qualitative Patient-Centered Outcomes Research Studies

    Dec 1, 2025, 00:00

  • PCR159 Mental and Behavioral Health Disorders MBHD Among Patients With Metastatic and Nonmetastatic Cancer: A Claims-Based Analysis

    Dec 1, 2025, 00:00

  • HPR186 Socioeconomic Disparities in Access to Treatment for Major Depressive Disorder: The Role of Accumulator and Maximizer Insurance Plans

    Dec 1, 2025, 00:00

  • EPH75 Epidemiological Characteristics and Economic Burden of IgA Nephropathy—a Retrospective Study Using Multicenter Electronic Medical Records Data in China

    Dec 1, 2025, 00:00

  • HTA77 Comparative Analysis of Economic Evaluation Frameworks for AI-Based Digital Health Technologies Across Four HTA Systems

    Dec 1, 2025, 00:00

  • HPR213 The Role of Regulatory Entities in Global Vaccine Availability

    Dec 1, 2025, 00:00

  • OP5 Economic and Organizational Impact of Subcutaneous Ocrelizumab in French Daily Hospitals

    Dec 1, 2025, 00:00

  • EE599 Optimization of the EVAR Pathway: An Integrated Organizational Model for Clinical Efficiency and Economic Sustainability

    Dec 1, 2025, 00:00

  • HSD51 From Admission to Discharge: Understanding the Transplant Patient Journey With German Statutory Health Insurance Claims Data

    Dec 1, 2025, 00:00

  • HTA60 Budget Impact Minimization Approaches Used Across Europe, Brazil, and Japan in the Reimbursement of Obesity Medications

    Dec 1, 2025, 00:00

  • SA17 Bigger, Better Studies: Prioritizing Literature Review Using an Approach Based on Large Language Models

    Dec 1, 2025, 00:00

  • MSR224 Which Generative AI Method Is Used for High Specificity? A Methodological Comparison From the Systemic Literature Review of the Burden of Influenza in France

    Dec 1, 2025, 00:00

  • EE471 Financing Sustainable Public Health: Design of a Herpes Zoster Prevention Bond to Fund Vaccination

    Dec 1, 2025, 00:00

  • HTA327 The Preferences for Advanced Therapy Medicinal Products: A Multicriteria Decision Analysis Framework

    Dec 1, 2025, 00:00

  • MSR204 Transparent, Traceable, and Reproducible Evidence Generation for HTA Using Generative AI and Retrieval-Augmented Generation (RAG)

    Dec 1, 2025, 00:00

  • CO158 Leveraging Generative AI for Efficient Patient Safety Narrative Drafting: A Semaglutide Case Study

    Dec 1, 2025, 00:00

  • HTA153 From Insight to Impact: Rethinking Pharma-Payer Partnerships to Enable Future Access in Europe

    Dec 1, 2025, 00:00

  • RWD130 One Research Objective, Many Realities: Mapping Data Availability and Governance Diversity in Oncology Research

    Dec 1, 2025, 00:00

  • CO7 Addressing the Inherent Challenges of the French National Claims Database (SNDS) Through Algorithms to Identify Patients With Diffuse Large B-cell Lymphoma (DLBCL) and Their Chemotherapy Treatments

    Dec 1, 2025, 00:00

  • EE631 Quantifying the Societal Value: Reduced Burden and Resource Savings From Baloxavir Marboxil's Influenza Transmission Protection in China

    Dec 1, 2025, 00:00

  • HTA118 Early Health Technology Assessment and Cost-Effectiveness of the National Cardiovascular Disease Prevention Program in Greece

    Dec 1, 2025, 00:00

  • MSR4 A Layered Approach to Reducing Hallucinations in LLMs for Structured and Unstructured Clinical Data

    Dec 1, 2025, 00:00

  • HTA154 From JCA to Local PR: Evaluating Impact Across Europe

    Dec 1, 2025, 00:00

  • HSD115 Treatment Patterns for Unresectable Locally Advanced or Metastatic Hormone Receptor-Positive HER2-Negative and Triple-Negative Breast Cancers in France

    Dec 1, 2025, 00:00

  • MT14 Digital Therapeutics in Europe: A Structured Review of Reimbursement and Access Pathways

    Dec 1, 2025, 00:00

  • HTA150 From Evidence Gaps to Launch Delays: A Review of Health Technology Assessment Critiques and Health Economics and Outcomes Research Strategy Readiness

    Dec 1, 2025, 00:00

  • PCR107 Health-Related Quality of Life Measured by EQ-5D Utility Among Patients With TGCT: A Trial-Based Analysis of EQ-5D Data From Patients in the MOTION Trial

    Dec 1, 2025, 00:00

  • HSD62 Improving Patient Flow and Multidisciplinary Coordination in Urothelial Carcinoma: Insights From Bulgarian Oncologists

    Dec 1, 2025, 00:00

  • EE243 Cost-Effectiveness of Control-IQ Hybrid Closed-Loop System in Adults With Type 1 Diabetes in Sweden

    Dec 1, 2025, 00:00

  • HTA234 Mind the Gap: Divergent Perceptions of Patient Engagement Value in Health Technology Assessment (HTA) Among Healthcare Providers and Patient Advocacy Groups in Israel

    Dec 1, 2025, 00:00

  • EE428 Estimating the Public Health and Economic Impact of Recombinant Zoster Vaccine (RZV) Vaccination for Adults Aged 50 and Older in South Korea

    Dec 1, 2025, 00:00

  • MSR44 Balancing Power and Interpretation: Responder Analysis vs. Mean Differences for PRO Endpoints in Oncology Clinical Trials

    Dec 1, 2025, 00:00

  • PCR3 A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Among Adolescents Aged 10-18 in China

    Dec 1, 2025, 00:00

  • CO52 Comparative Analysis of Patient-Reported Outcomes (PROs) in Asthma Biologic Late-Phase Studies and Approved Labels: Implications for Entry and Product Differentiation

    Dec 1, 2025, 00:00

  • EE466 Financial Impact of Dementia Care on Thai Households: A Multicenter Study of Informal Care Costs and Contributing Factors

    Dec 1, 2025, 00:00

  • HSD4 Advancing Real-World Evidence in Diffuse Large B-cell Lymphoma: Insights From EHR-Derived Data in the UK

    Dec 1, 2025, 00:00

  • RWD105 Inducing Labor in Denmark: A Descriptive Study

    Dec 1, 2025, 00:00

  • EE588 Modeling Framework for Assessing Cost-Effectiveness of New Treatments in Chronic Kidney Disease

    Dec 1, 2025, 00:00

  • PCR227 The Economic Burden of Amyotrophic Lateral Sclerosis: An Observational Study of Out-of-Pocket Expenses and the Impact on Caregivers

    Dec 1, 2025, 00:00

  • MSR82 Efficacy and Safety of Modern Biologics Compared to Conventional Therapies in AQP-4 Positive Neuromyelitis Optica Spectrum Disorder: A Fully AI-Automated Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA19 Accounting for Bereavement in NICE Pediatric Health Technology Appraisals: A Review of the Inclusion of Caregiver Health Utilities After the Death of a Child

    Dec 1, 2025, 00:00

  • EPH76 Epidemiological Insights in Merkel Cell Carcinoma Across Europe: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HTA133 Evaluating the Impact of Implementing AI-Assisted Contouring on Radiotherapy Staff and Workflows

    Dec 1, 2025, 00:00

  • HTA62 Budgetary Impact of Ultra-Rare Diseases in Brazil: A Review of Decisions From the Past Five Years

    Dec 1, 2025, 00:00

  • EE350 Economic and Clinical Impact of Older Adult Vaccination With the Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in Mexico

    Dec 1, 2025, 00:00

  • EE51 Analysis of the Breast Cancer Diagnosis Program: A Window of Opportunity

    Dec 1, 2025, 00:00

  • HTA172 Health Technologies Using Artificial Intelligen What Is Being Assessed in the UK by NICE?

    Dec 1, 2025, 00:00

  • PT6 Real-World Effectiveness, Safety Economic Impact, and Humanistic Outcomes of Bispecific Antibodies (BsAbs) in Third-or-Later-Line (3L+) Treatment of Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): A Systematic Review and Meta-An ...

    Dec 1, 2025, 00:00

  • EPH26 The Impact of Menopausal Hormone Therapy on Productivity and Health Care Utilization in Women: A Finnish Claims Database Study

    Dec 1, 2025, 00:00

  • SA48 Graphical Evidence Frameworks to Visualize the Holistic Value of Healthcare Interventions

    Dec 1, 2025, 00:00

  • HTA68 Challenges and Opportunities in the Dutch Lock Procedure Improving Access and Reimbursement Timelines for Cell and Gene Therapies in the Netherlands

    Dec 1, 2025, 00:00

  • EE717 The Long-Term Cost-Effectiveness of Insulin Icodec vs. Once-Daily Basal Insulin Analogs in Italy

    Dec 1, 2025, 00:00

  • EE578 Microcosting Analysis of Oral, Subcutaneous, and Intravenous Second-line Multiple Sclerosis Treatments Administered at Home or in Hospital

    Dec 1, 2025, 00:00

  • PCR183 Patient-Reported Stigma Across Health Conditions: Insights From the National Health and Wellness Survey (NHWS) in China

    Dec 1, 2025, 00:00

  • RWD4 A Real-World Retrospective Study on the Utilization of Antifibrotic Drugs in Greece During the Period 2019-2023

    Dec 1, 2025, 00:00

  • HTA178 How Do National Systems Take the JCA Into Account Navigating Specificities to Achieve Accelerated Patient Access?

    Dec 1, 2025, 00:00

  • RWD66 Disease Severity at Advanced Therapy Initiation in Real-World Psoriasis Patients in the US

    Dec 1, 2025, 00:00

  • CO100 EQ-5D Utility Impact of Worsening NYHA Class and CV Hospitalization (CVH) on Health-Related Quality of Life (HRQoL) of Patients With ATTR-CM Based on the ATTRibute-CM Trial

    Dec 1, 2025, 00:00

  • PCR246 Translation and Psychometric Validation of Brief Illness Perception Questionnaire: The Urdu Version

    Dec 1, 2025, 00:00

  • EE246 Cost-Effectiveness of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer Alongside the LIBELULE Randomized Phase III Trial

    Dec 1, 2025, 00:00

  • EE618 Productivity and Cost-Effectiveness of Initiative for Decentralized Cancer Care in Region Uppsala, Sweden

    Dec 1, 2025, 00:00

  • HSD91 Rare Disease Awareness Among Physicians in Five European Countries: Results of a Cross-Sectional Survey

    Dec 1, 2025, 00:00

  • PCR204 Quantifying the Societal Burden of Acanthamoeba Keratitis: Results From a Patient Survey

    Dec 1, 2025, 00:00

  • RWD92 Healthcare Resource Use and Mortality After Diabetic Ketoacidosis: Insights From Linked Primary- and Secondary-Care Data in the UK

    Dec 1, 2025, 00:00

  • EE727 The Socioeconomic Value of Adult Respiratory Immunization Programs in Spain: How Much Can We Gain From Expanding Prevention Efforts?

    Dec 1, 2025, 00:00

  • HSD99 Receipt of Biomarker Testing in Non-Small Cell Lung Cancer: Using Real-World Data to Identify Testing Gaps and Treatment Characteristics

    Dec 1, 2025, 00:00

  • MSR65 Country-Specific Adaptation of Health Economic Models With Generative AI: A Case Study in Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • EPH213 Sex Differences in Autoimmune Multimorbidity Across 11 Autoimmune Disorders in the Real-World Setting in Germany

    Dec 1, 2025, 00:00

  • EPH243 The Incidence and Survival of HPV-Positive and HPV-Negative Malignant Head and Neck Squamous Cell Carcinoma (HNSCC) in the United States: A Surveillance Epidemiology and End Results SEER 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • EE710 The Hidden Clinical and Economic Costs of PPI Treatment Failures in Severe Erosive Esophagitis

    Dec 1, 2025, 00:00

  • EE502 Healthcare Expenditure for Treatment of Cardiovascular Disease Among Hypercholesterolemia Patients in Japan: A Claims Data Analysis

    Dec 1, 2025, 00:00

  • P51 Catalogue of Actions to Address Policy Barriers of Drug Repurposing

    Dec 1, 2025, 00:00

  • EE722 The Role of Unpaid Work in Measuring the Social Costs of Disease

    Dec 1, 2025, 00:00

  • EE695 The Cost-Effectiveness of Using Site-Specific Wastewater-Based Surveillance to Monitor COVID-19 in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • EE354 Economic Burden and Unmet Need Among Adult Patients With Varying Patterns of Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program

    Dec 1, 2025, 00:00

  • PT14 The IMPACT Framework: A Value Assessment Framework for Holistic Health Technology Assessment

    Dec 1, 2025, 00:00

  • MSR105 Exploring Perspectives on Adult Pneumococcal Vaccination: A Qualitative Preference Study of Healthcare Providers (HCPs) and Healthcare Consumers (HCCs) in the United Kingdom and Italy

    Dec 1, 2025, 00:00

  • HPR136 Mapping Access Pathways for New Medicines in Finland: A Real-World Review of HTA and Reimbursement Decisions

    Dec 1, 2025, 00:00

  • EE605 Out-of-Pocket Expenditures of Families Affected by Epidermolysis Bullosa in Europe

    Dec 1, 2025, 00:00

  • HTA331 The Safety and Effectiveness of Drug-Induced Sleep Endoscopy in Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • EPH45 Clinical Profile of Asthma and Its Geographical Variability in Southern Spain

    Dec 1, 2025, 00:00

  • EPH14 Analysis of a Cancer Profile of 10 European States

    Dec 1, 2025, 00:00

  • EPH278 What Characteristics Are Associated With Having a Work Limitation Among United States Adults With Asthma?

    Dec 1, 2025, 00:00

  • HTA278 Real-World Evidence (RWE) and Its Impact on Scottish Medicines Consortium (SMC) Decisions: A Retrospective Review

    Dec 1, 2025, 00:00

  • MT15 Environmental Impact of Prefilled and Reusable Injectable Systems: A Systematic Review

    Dec 1, 2025, 00:00

  • RWD174 Signal Detection and Network Pharmacology Analysis of Paronychia Associated With eGFR Inhibitors

    Dec 1, 2025, 00:00

  • HPR80 Evolution of Manufacturer-Set List Prices and GKV Rebates for Orphan Drugs (OD) in Germany 2013-2024: How Much US WAC Is in German OD-Prices

    Dec 1, 2025, 00:00

  • HTA131 Evaluating GenAI for HTA Analogue Analysis: Identifying Rare Disease Approvals With Surrogate Endpoints and Single-Arm Trials

    Dec 1, 2025, 00:00

  • EE220 Cost-Effectiveness Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in Spain

    Dec 1, 2025, 00:00

  • CO29 Biomarker Levels in Patients With Crohn’s Disease Post-Advanced Therapy Induction: A Real-World Survey in Europe

    Dec 1, 2025, 00:00

  • PCR268 What Matters Most to Women in Breast Biopsy? A Discrete Choice Experiment in Italy

    Dec 1, 2025, 00:00

  • EPH274 Updated Projections of HPV Vaccine Coverage Growth in Europe: Are Countries on Track to Meet WHO's 2030 Target?

    Dec 1, 2025, 00:00

  • CO206 Real-World Observational Study of PAP Therapy Outcomes in Czech Patients With Sleep Apnea

    Dec 1, 2025, 00:00

  • EE161 Cost-Effectiveness Analysis of Ga-PSMA-11 PET/CT Imaging Followed by Lu-PSMA-617 vs. Standard of Care in Metastatic Castrate-Resistant Prostate Cancer

    Dec 1, 2025, 00:00

  • CO207 Real-World Outcomes and Economic Impact of Ribociclib in HR+/HER2- Advanced Breast Cancer: Evidence From the Portuguese REASSURE Cohort

    Dec 1, 2025, 00:00

  • EE591 Modeling What Matters: The Real-World Burden of Pregnancy-Related Complications in cTTP

    Dec 1, 2025, 00:00

  • RWD132 Out of Sight, Out of Mind? A Simulation Study Assessing the Use of Quantitative Bias Analysis for Outcome Misclassification in Single-Arm Trials With External Control Comparisons

    Dec 1, 2025, 00:00

  • EE180 Cost of First-Line Treatment of Hepatocellular Carcinoma With the Immune Checkpoint Inhibitor-Based Regimens STRIDE and Atezolizumab Plus Bevacizumab in Brazil

    Dec 1, 2025, 00:00

  • EE268 Cost-Effectiveness of Personalized Lifestyle Interventions in Obesity/Overweight: A Systematic Review

    Dec 1, 2025, 00:00

  • PCR168 Pain and Fatigue Assessment and Evaluation in Oncology Trials

    Dec 1, 2025, 00:00

  • EPH244 The Incidence, Mortality, and Survival of Breast Cancer per HER2/HR Status in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis

    Dec 1, 2025, 00:00

  • SA47 Global Trade Shocks and Exchange Rate Effects on Pharmaceutical Reference Pricing: Implications of EU Stimulus for US MFN Policy

    Dec 1, 2025, 00:00

  • MSR199 The HERC Database of Mapping Studies: A 2025 Update of a Live Systematic Review of Studies Predicting EQ-5D From Other Patient-Reported Outcome Measures

    Dec 1, 2025, 00:00

  • MSR147 Methods for Incidence Progression Estimation in Partitioned Survival Analysis: Does the Chosen Method Matter?

    Dec 1, 2025, 00:00

  • HTA328 The Rise of Optimization in NICE Guidan A Two-Decade Review With a Focus on Prevention

    Dec 1, 2025, 00:00

  • EE677 Systematic Literature Review of the Use of Generative AI in Health Economic Evaluation

    Dec 1, 2025, 00:00

  • EPH199 Public Health Impact of Herpes Zoster Vaccination in Immunocompromised Adults Aged 18-49 Years in the United Kingdom

    Dec 1, 2025, 00:00

  • EPH57 Descriptive Statistics and Polysubstance Use of Pregnant Women Admitted to the United States Treatment Facilities With Methamphetamine Use

    Dec 1, 2025, 00:00

  • MT8 Changes in Medical Technology Availability in Europe Between 2000 and 2020

    Dec 1, 2025, 00:00

  • MSR107 Facilitator-Led vs. Remote Components Within Structured Expert Elicitation of Survival Outcomes: A Targeted Review

    Dec 1, 2025, 00:00

  • EE685 The Artificial Intelligence Era in Health Economic Modeling

    Dec 1, 2025, 00:00

  • EE625 Quantifying the Economic Burden of Osteoarthritis in Portugal: Insights From a Patient Journey Model

    Dec 1, 2025, 00:00

  • PCR188 Potential Impacts of Participating in an HIV Cure-Related Trial With an Analytical Treatment Interruption on Partners: Qualitative Research Findings

    Dec 1, 2025, 00:00

  • EPH198 Public Health Impact of 25 Years of Pneumococcal Conjugate Vaccination in Children 5 Years Old: A Modeling Analysis

    Dec 1, 2025, 00:00

  • MSR184 Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer: A Network Meta-Analysis Comparing Treatments to Paclitaxel

    Dec 1, 2025, 00:00

  • HTA272 Predicting SMC Appraisal Outcomes Using Machine Learning: A Model to Support Early Market Access Strategy

    Dec 1, 2025, 00:00

  • PT23 Optimizing Market Access in Europe: A Comparative Analysis of Submission Templates from the EU JCA and National HTA Bodies (HAS, G-BA, ZIN, DMC)

    Dec 1, 2025, 00:00

  • MT44 Unraveling the Challenges of Multiplex Cell Culture Technology Using the HTA Core Model

    Dec 1, 2025, 00:00

  • EE230 Cost-Effectiveness Evaluation of RSVpreF Vaccine for Preventing RSV Among Older Adults With High Risk Under Taiwan National Vaccination Program

    Dec 1, 2025, 00:00

  • HSD7 Are Glucagon-Like Peptide-1 Receptor Agonists Prescribed for Weight Loss Slipping Through the Net of Japan’s Strict Guidelines? An Analysis of Health Insurance Claims Data

    Dec 1, 2025, 00:00

  • HPR3 A Comparative Analysis of Early Access Pathways in Italy and Fran Law 64896 vs. the French AAP

    Dec 1, 2025, 00:00

  • Physician-Directed Reinvestment: A Novel Cost-Savings Framework for Hospital Systems That Leverages Frontline Physicians

    Dec 1, 2025, 00:00

  • MSR140 Machine Learning Applications in Treatment Pattern Analysis Using Real-World Data: A Scoping Review

    Dec 1, 2025, 00:00

  • HPR116 Impact Of Reimbursement Policy On Medicines Expenditures And Copayment: The Case of Cardiovascular Medicines In Bulgaria

    Dec 1, 2025, 00:00

  • PT3 Radiographic Progression-Free Survival (rPFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line (1L) Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Meta-Analysis and Surrogate Threshold Effect

    Dec 1, 2025, 00:00

  • HSD98 Real-World Treatment Patterns of US Patients With Platinum-Resistant Ovarian Cancer

    Dec 1, 2025, 00:00

  • HTA104 Delayed Impact, Limited Leverage: Revenue Dynamics of Patent-Protected Drugs and the Effectiveness of Price-Volume Agreements in Germany

    Dec 1, 2025, 00:00

  • PCR210 Reliability Test of the Hungarian Versions of the Hypertension Knowledge Test and the QLICD-HY Quality of Life Assessment Questionnaire Among People With High Blood Pressure

    Dec 1, 2025, 00:00

  • EE606 Patient Blood Management With Intravenous Iron Is Economically Advantageous Compared to Usual Care in German Hospitals

    Dec 1, 2025, 00:00

  • PCR196 Psychometric Performance of EQ-HWB for Japanese Populations

    Dec 1, 2025, 00:00

  • MSR63 Cost-Effectiveness Modeling Based on a Clinical Trial Re-analysis Using Multimodal Machine Artificial Intelligence Methodology: Predicting Which Patients May Benefit Most From the Addition of Tremelimumab to Durvalumab Plus Chemothera ...

    Dec 1, 2025, 00:00

  • PCR105 Health Equity in Economic Analyses of Person-Centered Care: A Systematic Review

    Dec 1, 2025, 00:00

  • CO90 Efficacy and Safety of Antibody-Drug Conjugates (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EE586 Modeled Number and Cost of Biparametric Magnetic Resonance Imaging (bpMRI) Examinations in a Nationwide Prostate Cancer Screening Program: Utilizing the Results of the Czech Prostapilot Study

    Dec 1, 2025, 00:00

  • EE696 The Costs of Loneliness-Related Health Consequences in Finland

    Dec 1, 2025, 00:00

  • HTA308 Synthesizing Health Service Utilization Data for a Complex Intervention: A Case Study of Teledermatology

    Dec 1, 2025, 00:00

  • EE260 Cost-Effectiveness of Mixed Maternal RSVpreF/Infant Nirsevimab Immunization Approach vs. Nirsevimab Alone for the Prevention of Respiratory Syncytial Virus in Chile

    Dec 1, 2025, 00:00

  • PCR265 Wasfaty Improves Quality of Outpatient Pharmaceutical Service at a Tertiary Academic Hospital: A Descriptive Analysis

    Dec 1, 2025, 00:00

  • EPH187 Premature Mortality and Lost Productivity Due to HPV-Related Cancers in Europe

    Dec 1, 2025, 00:00

  • MSR93 Evaluating the Efficacy of Artificial Intelligence Models as Suitable Screening Tools in Systematic Reviews: The Example of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure Treatment

    Dec 1, 2025, 00:00

  • HTA174 Health Technology Assessment Landscape for Medical Devices in Europe

    Dec 1, 2025, 00:00

  • HPR70 ESMO-MCBS Evaluation and French Derogatory Access Decision: Is There a Correlation?

    Dec 1, 2025, 00:00

  • RWD2 A Hierarchical Algorithm to Identify Pregnancy Start and Duration Using Structured EHR Data

    Dec 1, 2025, 00:00

  • HPR18 AI for Pricing Reimbursement: When to Green-Light, When to Red-Light?

    Dec 1, 2025, 00:00

  • P60 The Social Impact of Health (SIoH) Framework: Capturing How Health-Driven Productivity Shapes National Development

    Dec 1, 2025, 00:00

  • RWD109 Integrating Mendelian Randomization With Real-World Eviden Cost-Effectiveness of Lipoprotein Testing for Primary Prevention of Cardiovascular Disease in High-Income Countries

    Dec 1, 2025, 00:00

  • HTA169 Harnessing Generative Artificial Intelligence for Global Value Dossier Development

    Dec 1, 2025, 00:00

  • CO259 Use of Encorafenib + Cetuximab EC in Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer (mCRC) in Real-World Settings: Data Visualization From a Pooled Dataset of European Observational Studies

    Dec 1, 2025, 00:00

  • EPH78 Epidemiology and Demographic Characteristics of Phenylketonuria in Brazil: A Real-World Data Study (2019-2024)

    Dec 1, 2025, 00:00

  • RWD182 Transforming Patient Journeys With Agentic AI

    Dec 1, 2025, 00:00

  • EE151 Conceptualizing an Economic Model Structure for Parkinson's Disease

    Dec 1, 2025, 00:00

  • HTA273 Prefilled Syringes in Anesthesiology: A Quantitative Assessment of Economic and Organizational Outcomes

    Dec 1, 2025, 00:00

  • HTA277 Readying for the Second Wave: What, When, and How Must Orphan Medicine Manufacturers Prepare for EU HTAR?

    Dec 1, 2025, 00:00

  • EE103 Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Obstruction in Italian Healthcare Service

    Dec 1, 2025, 00:00

  • PT17 Reconsidering Generic Utilities: Implications for Equitable Health Technology Appraisal

    Dec 1, 2025, 00:00

  • MSR18 AI Assistant Meets Human: Refining Methods for Research-Tailored AI Assistants to Support Global Product Strategy, Decision Making, and HEOR Impact

    Dec 1, 2025, 00:00

  • HPR203 The Impact of the COVID-19 Pandemic on the Performance of the Hospital Care System in Romania as Measured Using the Diagnosis-Related Groups (DRGs) Financing Technique

    Dec 1, 2025, 00:00

  • CO217 Safety Profile of Semaglutide in Obesity Management With or Without Type 2 Diabetes (T2DM): A Systematic Literature Review From Controlled and Real-World Settings

    Dec 1, 2025, 00:00

  • HTA276 Quality of Life and Productivity Costs in Cancer Patients Receiving Proton Therapy: A Predictive and Descriptive Study

    Dec 1, 2025, 00:00

  • MT10 Comparing Robotic-Assisted Coronary Artery Bypass Grafting Using the Da Vinci Surgical System to a Nonrobotic Approach: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • EE612 Potential Public Health Benefits of Recombinant Influenza Vaccines in Older Adults in England and Wales

    Dec 1, 2025, 00:00

  • HPR174 Regulatory Timelines for CMA Medicines In Italy: A Comparative Analysis of Pricing and Reimbursement Procedures

    Dec 1, 2025, 00:00

  • PT24 Comparative Analysis of Early Scientific Advice Mechanisms: EU JSC vs. National HTA Bodies (HAS, G-BA, NICE)

    Dec 1, 2025, 00:00

  • HSD64 Integrating CEUS in Diagnostic Pathways: Evidence of Economic and Organizational Sustainability From the Italian Healthcare System

    Dec 1, 2025, 00:00

  • EPH270 Unmet Need and the Public Health Grant: A Data-Driven Tool for Local Authority Spending Decisions

    Dec 1, 2025, 00:00

  • HPR206 The Innovative Licensing and Access Pathway (ILAP): Early Pathway Experience, Examining, Process Adaptations, and Industry Impact

    Dec 1, 2025, 00:00

  • EE608 Pharmacoeconomic and Healthcare Aspects of the TDM-Guided Decisions on Biological Treatment of Inflammatory Diseases: Systematic Review of International Evidence

    Dec 1, 2025, 00:00

  • HSD53 From Diagnosis to Treatment: Evaluating Timeliness and Treatment Patterns in Czech Pancreatic Cancer Patients

    Dec 1, 2025, 00:00

  • CO51 Clinical Utility of Multiplex Point of Care (PCR) Compared to Antigen Testing for Influenza-Like Illness in the Hospital Emergency Department

    Dec 1, 2025, 00:00

  • EPH229 The Burden of Patients With Severe Asthma: A Comparison Between Patients Treated With and Eligible for Monoclonal Antibodies Through a Retrospective Observational Analysis of Italian Real-World Data

    Dec 1, 2025, 00:00

  • EE388 Economic Evaluation of the Adoption of Peritoneal Dialysis for Newly Diagnosed Hemodialysis Ineligible Pediatric End-Stage Kidney Disease Patients in Egypt

    Dec 1, 2025, 00:00

  • HTA184 HTA Conflicts in Europe: Agreeing to Disagree?

    Dec 1, 2025, 00:00

  • Disclosure Information

    Dec 1, 2025, 00:00

  • EE687 The Budget Impact and Time Savings of Introducing Subcutaneously Administered Nivolumab and Hyaluronidase (NIVO SC) to Patients Receiving Intravenously Administered Nivolumab (NIVO IV) Across Indications in Canada

    Dec 1, 2025, 00:00

  • MSR46 Beyond the Mean: Do Distribution-Based Metrics Offer Greater Insight Into Predictors of Societal Health Preferences? A Secondary Analysis of 42 EQ-5D-5L Value Sets

    Dec 1, 2025, 00:00

  • HTA115 Do Short-Term Outcome-Based Payments for Treatments Provide the Same Incremental Net Benefit As List Price Discounts?

    Dec 1, 2025, 00:00

  • MSR118 Historical Shifts in Birth Month Distribution in Japan and the Impacts on Health Outcome Studies

    Dec 1, 2025, 00:00

  • EE523 Human Metapneumovirus (hMPV): Systematic Literature Review of Economic and Humanistic Disease Burden in Adults

    Dec 1, 2025, 00:00

  • CO72 Development of a Preliminary Conceptual Model to Capture the Adult Patient Experience of Follicular Lymphoma

    Dec 1, 2025, 00:00

  • EE490 Health Economic Assessment of Using Single-Operator Direct Visualization Cholangioscopy in the Management of Complex Bile Duct Stones in Saudi Arabia

    Dec 1, 2025, 00:00

  • MSR108 Feasibility Assessment of an Indirect Treatment Comparison of Seladelpar vs. Elafibranor in Patients With Primary Biliary Cholangitis

    Dec 1, 2025, 00:00

  • PCR108 Health State Utilities Associated With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

    Dec 1, 2025, 00:00

  • MSR8 A Novel Framework to Assess Noninferiority in National Institute for Health and Care Excellence (NICE) Cost-Comparison Evaluations (CCEs) Where Network Meta-Analyses (NMAs) Report Nonstatistically Significant Differences

    Dec 1, 2025, 00:00

  • HTA329 The Role of Environmental Evidence in HTA: Comparative Insights Into Global Assessment Frameworks

    Dec 1, 2025, 00:00

  • HTA344 Ukraine’s First Horizon Scanning Pilot: Lessons for HTA Implementation

    Dec 1, 2025, 00:00

  • MSR23 Ai-Augmented Data Extraction in Literature Reviews: Toward First-Pass Accuracy Competitive With Human Performance

    Dec 1, 2025, 00:00

  • EE336 Discrete Event Simulation and Treatment Sequencing Cost-Effectiveness Model in Second-Line Highly Active Relapse Remitting Multiple Sclerosis for a NICE Multiple Technology Appraisal

    Dec 1, 2025, 00:00

  • EE33 A Systematic Literature Review of Economic Evaluation Studies for Schizophrenia

    Dec 1, 2025, 00:00

  • EE346 Early Diagnosis and Treatment Optimization in Heart Failure Through NT-proBNP Testing in Primary and Specialist Care

    Dec 1, 2025, 00:00

  • EPH38 Care of Patients With Phenylketonuria (PKU) in Germany a Claims Data Analysis From 2013 to 2023

    Dec 1, 2025, 00:00

  • CO114 Examining the Trade-off of Breastfeeding vs. Semaglutide Use After Childbirth

    Dec 1, 2025, 00:00

  • CO247 The Relationship Between Surrogate Endpoints and Overall Survival in Myelofibrosis Clinical Trials: Results From a Targeted Literature Review

    Dec 1, 2025, 00:00

  • MSR59 Comparing Key European HTA Body Methodological Standards for Systematic Reviews of Economic and Utility Evidence

    Dec 1, 2025, 00:00

  • CO186 Preliminary Real-World Results of a Community Pharmacy-Based Intervention in COPD: Evidence From the Chronic Diseases From A to Z Program

    Dec 1, 2025, 00:00

  • SA96 The Use of Dynamic Models in Economic Evaluations in the UK and France

    Dec 1, 2025, 00:00

  • HTA359 What Are the Likely PICOs for Tovorafenib and Lifileucel as the First Products to Go Through the JCA?

    Dec 1, 2025, 00:00

  • PCR203 Quality-Adjusted Time Without Symptoms or Toxicity Q-TWiST Estimates in Previously Treated HER2-Positive Biliary Tract Carcinoma (BTC) Using the Zanidatamab HERIZON-BTC-01 Study

    Dec 1, 2025, 00:00

  • HPR63 Does the Joint Clinical Assessment (JCA) Enable Health Equity Across Europe? A Review of HTA Practices in the EU

    Dec 1, 2025, 00:00

  • PCR87 Evolution of High-Efficacy Therapies for Relapsing Multiple Sclerosis: Does Innovation Meet Patient Preferences?

    Dec 1, 2025, 00:00

  • EE615 Price Behavior of Originator Adalimumab After Biosimilars Entry: Evidence From the Colombian Market

    Dec 1, 2025, 00:00

  • EE736 Treatment Patterns and Healthcare Resource Utilization in Patients With Chronic Inflammatory Demyelinating Polyneuropathy in England: A Retrospective, Observational Cohort Study

    Dec 1, 2025, 00:00

  • CO167 Multimorbidity and Health-Related Quality of Life Among Adult Population in the United States

    Dec 1, 2025, 00:00

  • MT30 Multi-Country Survey to Explore Clinicians Experiences on a New Imaging Technology for Gastrointestinal Endoscopes and Its Impact on Detection and Resection of Lesions

    Dec 1, 2025, 00:00

  • PCR125 Identifying Factors Associated With Involvement in Healthcare Decisions in Wales

    Dec 1, 2025, 00:00

  • HTA301 Stakeholder Involvement in the Health Technology Assessment Process in Ukraine

    Dec 1, 2025, 00:00

  • HPR35 Benefits and Challenges in the Implementation of EU HTAR for Medical Devices: Lessons Learned From the Pharmaceutical Industry

    Dec 1, 2025, 00:00

  • PCR185 Perspectives of Patients and Caregivers on Relapsed/Refractory Acute Myeloid Leukemia Treatments: A Mixed-Methods Interview Study

    Dec 1, 2025, 00:00

  • HTA149 From Efficiency to Equity: Considerations in NICE Technology Appraisals

    Dec 1, 2025, 00:00

  • EE182 Cost of Treatment of Metastatic Non-Small Lung Cancer in Sweden, 2011-2023

    Dec 1, 2025, 00:00

  • SA5 A Systematic Literature Review on Economic Evaluations and Cost-Effectiveness of Second-Line Treatment Options for Immune Thrombocytopenia

    Dec 1, 2025, 00:00

  • EE754 What Tips the Scale Toward Reimbursement? A Dutch-led Comparison of Pharmacoeconomic Evaluations Across the Netherlands, Sweden, and the United Kingdom

    Dec 1, 2025, 00:00

  • EPH235 The Fiscal Case for Investing in COVID-19 Vaccination: A UK Treasury Perspective

    Dec 1, 2025, 00:00

  • CO17 Assessment of Newly Developed Medication Adherence Tool in Rural Community Pharmacies

    Dec 1, 2025, 00:00

  • PCR195 Psychometric Evaluation of the Impact of Weight on Quality of Life–Lite Clinical Trials (IWQOL-Lite-CT) Version in Adults Participating in a Pharmacological Clinical Trial for Obesity

    Dec 1, 2025, 00:00

  • HPR29 Assessing Stakeholders’ Perceptions of the EU Health Technology Assessment Regulation and Access to Innovative Medicines in Europe and the Netherlands: Challenges, Opportunities, and Recommendations

    Dec 1, 2025, 00:00

  • EE109 Budget Impact of Introducing an Omalizumab Biosimilar in 23 European Countries

    Dec 1, 2025, 00:00

  • EE613 Preliminary Observational Analysis of Digital Health Platform Associated With Medical Cost Changes in Employer Population

    Dec 1, 2025, 00:00

  • HPR176 Review and Horizon Scanning of Advanced Therapy Medicinal Products in Slovenia: Registration, Reimbursement, and Future Pipeline

    Dec 1, 2025, 00:00

  • HTA283 Reference Framework, Key Decision-Making Factors, and the Impact of Critical Parameters on Listing Recommendations for Nononcologic Drugs for Rare Diseases Issued by Canadian HTA Bodies

    Dec 1, 2025, 00:00

  • CO256 UDCA Treatment Response in Primary Biliary Cholangitis in the United States

    Dec 1, 2025, 00:00

  • PCR27 Association Between Subjective Sleep Quality and Quality of Life (QoL) Linked With Claims Data in the DeSC Healthcare Database in Japan

    Dec 1, 2025, 00:00

  • HSD122 Utilization of Informal WhatsApp for Pre- and Postnatal Referral Services in the Kwadaso Municipality of Ghana

    Dec 1, 2025, 00:00

  • EE561 Is Lecanemab Worth the Wait? Real Option Value and the Cost of Future Innovation in Alzheimer's Disease

    Dec 1, 2025, 00:00

  • EPH138 Important Risk Factors to Proxies of Treatment Failures in Patients With Major Depressive Disorder: Insights From a Claims Database Study

    Dec 1, 2025, 00:00

  • EPH30 Budget Impact of an Organized Colorectal Cancer Screening in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • HTA146 Exploring Nordic Real-World Evidence Sources for a PICO Assessment of a Hypothetical Oncology Drug and Medical Device Product

    Dec 1, 2025, 00:00

  • PCR249 Treatment Preferences in Adults With Chronic Spontaneous Urticaria in Italy: Insights From the CHOICE-CSU 2 Study

    Dec 1, 2025, 00:00

  • EPH266 Uncovering Gender Disparities in Secondary Care for Major Adverse Cardiovascular Events (MACE): Insights From the Hospital Episodes Statistics (HES) Database

    Dec 1, 2025, 00:00

  • HPR195 The Czech Republic’s Dedicated Orphan Drug Reimbursement Mechanism 2022-2025: Improvements in Access

    Dec 1, 2025, 00:00

  • P30 Assessment of Mortality and COPD Exacerbations in GOLD E COPD Patients in the Netherlands

    Dec 1, 2025, 00:00

  • PT1 A Contemporary Approach to Determining Cancer Patients Healthcare Resources Utilization

    Dec 1, 2025, 00:00

  • EE699 The Economic Burden of Diabetes-Related Blindness and Vision Impairment in Saudi Arabia

    Dec 1, 2025, 00:00

  • MSR109 Fitting Flexible Survival Models to Landmark Survival Estimates in R

    Dec 1, 2025, 00:00

  • P44 Early Economic Modeling to Estimate Cost-Effectiveness and Value-Based Price of a Gene Therapy for Urofacial Syndrome

    Dec 1, 2025, 00:00

  • EPH70 Effects of Antidepressant Drug Classes on Dementia Risk: A 23-Year Cohort Study Using Akrivia Health Secondary Mental Health Data

    Dec 1, 2025, 00:00

  • HPR179 Rising Costs in Pharmaceutical Services: A Decade of Prescription Spending Trends in Türkiye 2015-2024

    Dec 1, 2025, 00:00

  • SA74 Patient Characteristics and Treatment Comparison Among Patients With Chronic Obstructive Pulmonary Disease: Real-World Evidence From Sweden

    Dec 1, 2025, 00:00

  • Measuring the First Mover Advantage in US Biosimilar Markets

    Dec 1, 2025, 00:00

  • PCR37 Capturing the Realities of Hematological Cancer Patients’ Experiences of Novel Immunotherapies: A Call for Alignment and Action to Improve PROM Within CAR-T and Bispecific Antibody Therapies

    Dec 1, 2025, 00:00

  • SA85 Simulating Patient Journeys in Heart Failure to Optimize Treatment Pathways: An Agent-Based Modeling Study

    Dec 1, 2025, 00:00

  • MSR170 Predicting PICOs Through Machine-Learning–Powered Information Compression and Statistical Ranking

    Dec 1, 2025, 00:00

  • PCR103 Generalizability of Patient Preference Study Results: A Weight and Test Approach

    Dec 1, 2025, 00:00

  • HTA36 Application of Budget Impact Model in Evaluation of P2P Payment Strategy in US Health Systems

    Dec 1, 2025, 00:00

  • MSR124 How Publication Bias May Overestimate the Risk of Serious Adverse Events Associated With Bisphosphonate Use

    Dec 1, 2025, 00:00

  • EE298 Cost-Utility Analysis of Add-On Vericiguat to Standard Treatment in Thai Patients With Heart Failure and Reduced Ejection Fraction

    Dec 1, 2025, 00:00

  • HTA38 Are Real-World Survival Outcomes in Metastatic Breast Cancer Transportable Between the US and Austria?

    Dec 1, 2025, 00:00

  • EE82 Budget Impact Analysis of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective

    Dec 1, 2025, 00:00

  • EE86 Budget Impact Analysis of High-Energy High-Protein (HEHP) Oral Nutritional Support (ONS) for the Treatment of Disease-Related Malnutrition (DRM) in Cancer Patients in the French Community Setting

    Dec 1, 2025, 00:00

  • HTA140 Evolution of Health Technology Assessment (HTA) in India: A Scoping Review and Thematic Analysis

    Dec 1, 2025, 00:00

  • HPR155 Patient-Reported Outcomes Used for Regulatory Approval of Oncology Medicinal Products in the European Union Between 2021 and 2024: A Review Update

    Dec 1, 2025, 00:00

  • EE583 Model Structure Variability in NICE HTAs: Evidence From Asthma and TMA Appraisals to Support the Need for Disease-Specific Reference Models

    Dec 1, 2025, 00:00

  • HPR8 A Retrospective Analysis of Reimbursement Timelines in Ireland: What Does a 10-Year Analysis Show?

    Dec 1, 2025, 00:00

  • PT28 Cross-Validation of the Glycated Hemoglobin HbA1c Translator: A Predictive Tool to Evaluate the Relationship Between Diabetes Complications and Associated Healthcare Costs

    Dec 1, 2025, 00:00

  • EQ Health and Wellbeing EQ-HWB: A Psychometric Assessment Across 6 Conditions and the General Population in the United Kingdom

    Dec 1, 2025, 00:00

  • EE285 Costs and Health Outcomes of Meek Skin Micrografting vs. Mesh Skin Grafting in Adult Patients With Deep Partial Thickness and/or Full-Thickness Small (Burn) Wounds

    Dec 1, 2025, 00:00

  • HTA319 The Impact of Clinical Evidence on the Inclusion of Non-Small Cell Lung Cancer Drugs in Brazil's Supplementary Healthcare System

    Dec 1, 2025, 00:00

  • RWD131 Oracle Real-World Data: Analysis of the Characteristics and Representativeness of Oracle's Linked EHR-Claims Database

    Dec 1, 2025, 00:00

  • CO48 Clinical Outcomes Associated With Pembrolizumab Immunotherapy in Mesothelioma: A Systematic Review

    Dec 1, 2025, 00:00

  • EPH111 Five-Year Inpatient Hospital Trends of COVID-19 Admissions in US Medicare Fee for Service

    Dec 1, 2025, 00:00

  • CO30 Biomarker Levels in Patients With Ulcerative Colitis Post-Advanced Therapy Induction: A Real-World Survey in Europe

    Dec 1, 2025, 00:00

  • HTA144 Exploring Evidence Gaps in National Institute for Health and Care Excellence Early Value Assessments

    Dec 1, 2025, 00:00

  • HPR120 Implications of Recent US Policy Changes on Evidence Generation Requirements for Enabling Access to Medicines and Vaccines in Low- and Middle-Income Countries

    Dec 1, 2025, 00:00

  • SA67 Medical and Nonmedical Resource Utilization Associated With CIDP: Results From a Real-World International Survey

    Dec 1, 2025, 00:00

  • CO42 Clinical and Economic Outcomes of Cannabis-Based Formulations (CBD and CBD/CBG) for Autism Spectrum Disorder (ASD): A HEOR Model Study Analysis

    Dec 1, 2025, 00:00

  • EPH145 Increases in Frailty Following Hospitalization With COVID-19: An Analysis of Claims and Annual Health Check Data

    Dec 1, 2025, 00:00

  • HTA349 Use of AI Methods in NICE Technology Appraisals: What Is the Current Status Quo?

    Dec 1, 2025, 00:00

  • EE241 Cost-Effectiveness of ColonFlag in Austria: A Model-Based Evaluation

    Dec 1, 2025, 00:00

  • HTA256 NICE Technology Appraisal Submissions for Non-Small Cell Lung Cancer: Analysis and Insights

    Dec 1, 2025, 00:00

  • HSD87 Pharmacists’ Engagement With Pharmaceutical Care in Pakistan: Insights From a Cross-Sectional Survey on Knowledge, Attitudes, Practices, and Barriers

    Dec 1, 2025, 00:00

  • EE559 Intra-Procedure Cost Variability: A Retrospective Analysis of Real-World Patient Level Information Costing (PLICS) Data for a Minimally Invasive BPO Therapy in the NHS

    Dec 1, 2025, 00:00

  • HSD30 Current Treatment Pathway for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in England: Insights From a Qualitative Validation With Clinical Experts

    Dec 1, 2025, 00:00

  • P50 Evaluating Personalized Care for Rare Disease: A Decision-Analytic Framework for Patient-Centered Solutions in Multiple System Atrophy

    Dec 1, 2025, 00:00

  • P58 An Evaluation Framework for Healthcare Professionals’ Digital Health and AI Technologies: Evidence-Based Policy Recommendations

    Dec 1, 2025, 00:00

  • PCR15 An Initiative to Improve Patient Organization Engagement at the National Center for Pharmacoeconomics, Ireland

    Dec 1, 2025, 00:00

  • EE11 A Cost-Effectiveness Analysis of Ustekinumab Against Vedolizumab Among Inflammatory Bowel Disease Patients With Extra-intestinal Manifestations in Egypt

    Dec 1, 2025, 00:00

  • RWD175 Study Design Trends in Registry-Based Oncology Studies: Analysis of HMA-EMA Real-World Data Catalogs

    Dec 1, 2025, 00:00

  • CO137 Impact of Disease Progression on Healthcare Resource Utilization and Quality of Life in Patients With Hypertrophic Cardiomyopathy: A Real-World Cross-Sectional Survey

    Dec 1, 2025, 00:00

  • EPH6 A Real-World Study on Italian Administrative Healthcare Data to Describe Patients With Chronic Obstructive Pulmonary Disease by Therapeutic Pattern and Exacerbation Rate

    Dec 1, 2025, 00:00

  • EPH42 Characteristics Associated With the Presence of a Functional Limitation Among Adults With Asthma in the United States: Findings From the Medical Expenditure Panel Survey Study

    Dec 1, 2025, 00:00

  • EE35 A Systematic Review of the Methods and Quality of Economic Evaluations for AI-Assisted Cancer Screening or Diagnosis

    Dec 1, 2025, 00:00

  • RWD91 Healthcare Resource Use Among Children With Mucopolysaccharidosis Type III MPS III: A Retrospective Claims Database Analysis in the US

    Dec 1, 2025, 00:00

  • EE746 Utilization and Patient Characteristics of Robotic-Assisted Colorectal Surgery in Germany: A Claims Data Analysis

    Dec 1, 2025, 00:00

  • MSR40 Assessing Known Groups and Convergent Validity of the EQ-5D-5L in Assessing the Health-Related Quality of Life of Individuals With Obesity Who Have and Have Not Received Bariatric Surgery

    Dec 1, 2025, 00:00

  • HPR1 ComboConnect—Bridging Access Gaps in Combination Therapies: An Italian Project in Collaboration With ISPOR Italy-Rome Chapter

    Dec 1, 2025, 00:00

  • MSR135 Key Risk Indicators in eCOA: Considerations for Improving eDiary Data Quality and Regulatory Compliance

    Dec 1, 2025, 00:00

  • HTA187 HTA Life-Cycle Concepts: The Need for HTA Bodies to Grow Beyond Their Traditional Scope

    Dec 1, 2025, 00:00

  • HSD44 Environmental Impact of Psychiatric Outpatient Visit: Emissions Analysis of Travel and the Sustainability Potential of Remote Consultations

    Dec 1, 2025, 00:00

  • CO58 Comparative Efficacy of Iptacopan Monotherapy vs. Danicopan Add-on to C5i in Paroxysmal Nocturnal Hemoglobinuria (PNH) Results From an Indirect Treatment Comparison (ITC)

    Dec 1, 2025, 00:00

  • MSR166 Personalized Treatment Optimization Using Reinforcement Learning on Real-World Data (RWD)

    Dec 1, 2025, 00:00

  • P20 The Frequency of Mentions and Impact of Patient Input in HTA Decision Making in Cell and Gene Therapies Across the UK, Canada, and Australia

    Dec 1, 2025, 00:00

  • SA90 Systematic Review of Doubly Robust Methods for Population-Adjusted Indirect Comparisons

    Dec 1, 2025, 00:00

  • HPR198 The Effect of Pharmaceutical Pricing Policies on Healthcare Expenditures in Turkey: Analysis for the Period 2015-2024

    Dec 1, 2025, 00:00

  • P18 Mixed-Method Exploration of Visual Analogue Scale (VAS) Variations to Measure Health, Social Care, and Carer-Related Quality of Life (QoL)

    Dec 1, 2025, 00:00

  • RWD98 Hospital Burden of Pulmonary Arterial Hypertension in Fran A Real-World Study Using the French Hospitalization Database (PMSI)

    Dec 1, 2025, 00:00

  • CO244 The Incidence and Economic Impact of Major Adverse Events Associated With Intravascular Temperature Management: A Systematic Review, Analysis, and Model

    Dec 1, 2025, 00:00

  • PT15 Development of the Eating Drivers Diary (EDDY): A Novel Patient-Reported Outcome Measure for Use in Clinical Trials of Medications for Weight Reduction

    Dec 1, 2025, 00:00

  • RWD82 Expediting Oncology Evidence Generation by Leveraging EMR-Enabled Clinically Rich Real-World Data at Scale

    Dec 1, 2025, 00:00

  • PCR45 Cognitive Debrief of the PROMIS Parent Proxy Mobility Item Bank in Caregivers of Children Living With Duchenne Muscular Dystrophy

    Dec 1, 2025, 00:00

  • PT37 Economic Evaluation of I-Medicine: An AI-Driven E-Medicine Platform for Reducing Adverse Drug Reactions and Healthcare Expenditures

    Dec 1, 2025, 00:00

  • EE89 Budget Impact Analysis of Introducing Nirsevimab Into the National Immunization Program for Infants in Korea

    Dec 1, 2025, 00:00

  • EE183 Cost per Responder Analysis of Bimekizumab, a Monoclonal IgG1 Antibody Which Selectively Inhibits Il17f in Addition to Il17a Against Il17a Inhibitors in the Treatment of Axial Spondyloarthritis in Finland

    Dec 1, 2025, 00:00

  • EE159 Cost Comparison of Symptom Treatment in Atopic Dermatitis Using Upadacitinib and Dupilumab in Poland

    Dec 1, 2025, 00:00

  • PCR237 The Mental Health Burden of Rare Diseases Based on Insights From Patients and Caregivers Through Rarepulse® Social Listening

    Dec 1, 2025, 00:00

  • EPH219 Strong But Do They Ask for Help? Mental Health of Young Athletes

    Dec 1, 2025, 00:00

  • P14 Cost-Effectiveness Modeling of Test and Treat Strategies: A Diagnosis of Over-Complexity

    Dec 1, 2025, 00:00

  • EE726 The Socioeconomic Value of Adult Respiratory Immunization Programs in Fran Can Improved Coverage Unlock Missed Gains?

    Dec 1, 2025, 00:00

  • HTA105 Determinants of Willingness to Pay Thresholds in NICE Oncology Technology Appraisals

    Dec 1, 2025, 00:00

  • PT38 Efficacy and Safety of Nalbuphine Compared With Analgesics for Moderate to Severe Postoperative Pain: A Systematic Review and Network Meta-Analysis

    Dec 1, 2025, 00:00

  • EPH84 Estimated Healthcare Resource Utilization and Costs Associated With Semaglutide Life Expectancy Gains in a Real-World Population With CVD and Overweight or Obesity in the United Kingdom

    Dec 1, 2025, 00:00

  • HTA87 Comprehensive Clinical Evaluation of Drugs for Moderate-to-Severe Chronic Obstructive Pulmonary Disease

    Dec 1, 2025, 00:00

  • RWD149 Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data

    Dec 1, 2025, 00:00

  • HTA125 Ensuring Greater Acceptance of Minimal Residual Disease Negativity in Health Technology Assessments in Multiple Myeloma: Key Barriers and Opportunities

    Dec 1, 2025, 00:00

  • CO210 Reducing Healthcare Costs and Addressing Health Equity Through Improved Treatment Adherence and Reduced Exacerbation Risk in Chronic Obstructive Pulmonary Disease: Real-World Evidence From a Danish Nationwide Cohort Study

    Dec 1, 2025, 00:00

  • EPH140 Incidence and Prevalence of Primary Biliary Cholangitis (PBC) and Cholestatic Pruritus (CP) in Germany: Results From a Statutory Health Insurance (SHI) Claims Analysis

    Dec 1, 2025, 00:00

  • P36 The Value of the Health and Well-being Benefits of Healthcare Facilities Outdoor Spaces

    Dec 1, 2025, 00:00

  • SA45 Gaps in JCA Guidance for Systematic Literature Reviews: A Comparative Review with Cochrane, EUnetHTA, and Major HTA Agencies' Standards

    Dec 1, 2025, 00:00

  • PCR1 Too Good to Be True? Social Desirability Bias in Age-Related Patterns of Self-Reported Medication Adherence Among Patients With Atrial Fibrillation

    Dec 1, 2025, 00:00

  • EE1 Care Now, Pay Later (CNPL): Evaluating the Budgetary and Access Implications of a Novel Financing Model for Inclisiran in Atherosclerotic Cardiovascular Disease (ASCVD) Patients in India

    Dec 1, 2025, 00:00

  • EPH149 Integrated Sustainability Assessment of the Population-Based Colorectal Cancer Screening Program in Flanders

    Dec 1, 2025, 00:00

  • HTA369 Who Speaks For Europe? A Country-Level Analysis Of Representation And Expertise In EU Health Technology Assessment Joint Bodies

    Dec 1, 2025, 00:00

  • EE141 Comparing Alternative Extrapolation Methods Using Standard Partitioned Survival Model Functionality in the Presence of Converging Survival Data: A Case Study in Renal Cell Carcinoma

    Dec 1, 2025, 00:00

  • EE483 Has the IRA Impacted International Price Differentials? Comparing US and German Drug Prices in the Era of MFP

    Dec 1, 2025, 00:00

  • HSD5 AI-Enabled Extraction of eGFR and BRAF Testing Patterns in Advanced NSCLC: IMPACT-NSCLC, a Multicenter Real-World Study (2019-2024)

    Dec 1, 2025, 00:00

  • SA71 Natural Language Processing for Identification of Negative Symptoms in Patients With and Without Cognitive Impairment Associated With Schizophrenia (CIAS)

    Dec 1, 2025, 00:00

  • HPR220 Towards Shaping Rare Diseases and Orphan Drugs Health Ecosystem in Saudi Arabia

    Dec 1, 2025, 00:00

  • PCR33 Bimekizumab Led to Sustained Improvements in Health-Related Quality of Life and Work Productivity in Patients With Axial Spondyloarthritis: 3-Year Results From Two Phase 3 Studies

    Dec 1, 2025, 00:00

  • CO45 Clinical Efficacy and Safety of Targeted Therapies for HER2 Mutant Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • RWD157 Real-World Evidence Study on PD-L1 Testing and Use of Immuno-Oncology (IO) Treatments Among Cancer Patients in the Helsinki and Uusimaa (HUS) Region, Finland

    Dec 1, 2025, 00:00

  • EE273 Cost-Effectiveness of Rozanolixizumab vs. Efgartigimod in the Treatment of Generalized Myasthenia Gravis (gMG) in Greece

    Dec 1, 2025, 00:00

  • CO225 Systematic Literature Review (SLR) of Efficacy, Health-Related Quality of Life (HRQoL), and Safety of the First-Line (1L) Treatments of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    Dec 1, 2025, 00:00

  • RWD17 An Algorithm to Identify Immunocompromised Patients in French Claims Data for Rapid Preventive or Therapeutic Interventions

    Dec 1, 2025, 00:00

  • PCR264 Variability in Health Utility Scores in Pancreatic Cancer: Findings From a Targeted Literature Review

    Dec 1, 2025, 00:00

  • HPR214 The Role of Technological Innovation and Policy in the Evolution of Care Models in Italy

    Dec 1, 2025, 00:00

  • PCR43 Characterizing and Quantifying Impacts of Neuromyelitis Optica Spectrum Disorder (NMOSD) on Patients and Caregivers

    Dec 1, 2025, 00:00

  • RWD164 Real-World Treatment Patterns and Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Previously Treated With First-Line (1L) Platinum-Based Chemotherapy (PBC)

    Dec 1, 2025, 00:00

  • PCR241 The Reliability and Validity of the Greek Version of the Pediatric Quality of Life Inventory™ 30 Duchenne Muscular Dystrophy Module in Children With Duchenne Muscular Dystrophy

    Dec 1, 2025, 00:00

  • PCR255 Understanding Treatment Preference Heterogeneity in Psoriasis: Insights From a Qualitative Analysis of Social Media Data

    Dec 1, 2025, 00:00

  • EPH98 Examination of Attitudes Towards Vaccinations Among the Hungarian Population

    Dec 1, 2025, 00:00

  • HSD28 COVID-19's Effects on Mental Health Services: The Effectiveness of Telepsychiatry and Challenges in Substance Use Disorders in the United States

    Dec 1, 2025, 00:00

  • HTA101 Cross-Agency Analysis of Six-Minute Walk Test (6MWT) Adoption in Muscular and Nonmuscular Neurological HTA Submissions: Assessing Surrogate Endpoints for Disease Progression

    Dec 1, 2025, 00:00

  • RWD77 Evaluating a Potential Link Between Alprazolam and Intracranial Aneurysm: A Pharmacovigilance and Bioinformatics Approach Through FAERS and Molecular Docking

    Dec 1, 2025, 00:00

  • HPR222 Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-offs

    Dec 1, 2025, 00:00

  • EE537 Impact of Mucus Plugs on the Health Economic Burden in Chronic Obstructive Pulmonary Disease (COPD) Patients

    Dec 1, 2025, 00:00

  • HPR189 Stakeholder Mapping and Policy Assessment of Rare Diseases in Southeast Asia

    Dec 1, 2025, 00:00

  • HSD84 Patterns of Treatment Adherence and Administration Preferences for People With Transthyretin Amyloid Cardiomyopathy: A Real-World Survey in Europe, the United States, and Japan

    Dec 1, 2025, 00:00

  • EPH173 Opportunity Gain in Resources as New Framework to Counterpart Burnout in Healthcare Systems

    Dec 1, 2025, 00:00

  • HTA198 Importance of Decisional Context in the Health Technology Assessment (HTA) of Ultra-Orphan Drugs

    Dec 1, 2025, 00:00

  • EE403 Economic Modeling in Ophthalmology: Reimagining Cost-Effectiveness Model Structures

    Dec 1, 2025, 00:00

  • EPH258 Treatment Patterns in Epithelial Ovarian Cancer (EOC) With a Focus on Recurrent EOC and PARPi Progressors: A Targeted Literature Review Across Selected Countries

    Dec 1, 2025, 00:00

  • HTA70 Challenges in Defining Target Populations: An Analysis of Orphan Drug Health Technology Assessments in Germany 2024

    Dec 1, 2025, 00:00

  • PCR63 Development of Two Versions of a Patient-Preference Questionnaire for Evaluating Potential HIV Cure-Related and Other HIV Interventions

    Dec 1, 2025, 00:00

  • HTA143 Examining the Relationship Between the NICE WTP Threshold and the Severity Modifier

    Dec 1, 2025, 00:00

  • EE355 Economic Burden Associated With Type 2 Diabetes Mellitus in Fran An Update From the National Insurance Claim Database

    Dec 1, 2025, 00:00

  • HSD57 Hospital Community Integration: The Case of the Territorial Oncology Center at ASL 04 Teramo

    Dec 1, 2025, 00:00

  • PCR35 Can We Quantify the Financial Impact of Patient-Reported Outcomes on the Value of Oncology Products?

    Dec 1, 2025, 00:00

  • EE330 Dihydropyrimidine Dehydrogenase (DPYD) Genetic Testing Before Fluoropyrimidine-Based Adjuvant Chemotherapy for Colorectal Cancer in Qatar: A Cost-Effective Approach

    Dec 1, 2025, 00:00

  • RWD41 Comparing the Addition of Natural Language Processing (NLP) to US Electronic Health Records (EHRs): Insights Into Extracting Predicted Forced Vital Capacity (PpFVC) From Unstructured Clinical Notes

    Dec 1, 2025, 00:00

  • MSR102 Exploring Artificial Intelligence's (AI's) Role in Literature Screening: A Comparative Analysis Paving the Way for More Efficient Evidence Synthesis

    Dec 1, 2025, 00:00

  • RWD171 Scaling Responsible Healthcare Data Access With AI-Driven Sensitive Patient Variable Detection

    Dec 1, 2025, 00:00

  • SA87 Systematic Literature Review SLR Characterizing Humanistic Disease Burden and Unmet Needs in Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)

    Dec 1, 2025, 00:00

  • HTA4 A Comprehensive Review of Health Technology Reassessments for Oncology Drugs in Fran Impact on Reimbursement Outcomes 2019-2024

    Dec 1, 2025, 00:00

  • P3 Zoom In: Uncovering Clinical Nuance in Simplified Health Economic Model Structure Through Artificial Intelligence

    Dec 1, 2025, 00:00

  • HPR161 Physicians’ Knowledge, Attitude, and Practice Regarding Medical Liability: A Study in Saudi Arabia

    Dec 1, 2025, 00:00

  • P29 Do Older People Always Prefer Avoiding Nursing Homes? Evidence in France From a Mixed-Methods Approach

    Dec 1, 2025, 00:00

  • CO33 Bridging the Regulatory-Payer Evidence Gap: A Case Study With Six Minute Walk Distance and Mortality

    Dec 1, 2025, 00:00

  • RWD73 Economic Burden of Type 1 Diabetes Mellitus After Disease Onset: A Claims Data Analysis

    Dec 1, 2025, 00:00
  • 1
  • 2 (current)
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »